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A B S T R A C T   
Background: Splenectomy is a surgical intervention for a variety of indications; benign and malignant. Compli-
cations of this procedure include Venous thromboembolism (VTE) and infection. The incidence of VTE post- 
surgery has been reported between 0.8%–3% depending on the type of surgery. A higher incidence of abdom-
inal VTE was reported post splenectomy (6–11%). However, there is limited literature regarding the risk factors 
for post splenectomy VTE and the optimal strategy for thromboprophylaxis. 
Objective: The primary objective of the study was to evaluate the incidence of VTE post splenectomy and to 
identify the pre-operative, intra-operative and post-operative risk factors. The secondary objective was to assess 
the local compliance with post-splenectomy prophylactic antibiotics and vaccination protocols. 
Methods: We conducted a retrospective observational study. All patients who had a splenectomy in St James’s 
Hospital between January 2007 and June 2017 were included and reviewed. Statistical analysis was carried out 
using SPSS statistical package. 
Results: 85 patients were involved in the study. The main indications for splenectomy were benign haematology, 
malignant haematology, solid tumours, traumatic and spontaneous rupture. 6/85 patients developed VTE 
(7.06%). 
High BMI ≥ 30 was associated with increased risk of VTE (p = 0.007), while the use of post-operative pro-
phylactic anticoagulation was associated with reduced risk (p = 0.005). Other factors including age >50 years, 
female gender, presence of active malignancy and splenomegaly were associated with increased VTE risk with no 
statistical significance. All VTE’s occurred in elective versus emergency splenectomy. Laparoscopic splenectomy 
was associated with higher risk of VTE than open splenectomy. 97% of patients were prescribed prophylactic 
antibiotics on discharge, but only 88% had received recommended vaccinations. 
Conclusion: Venous thromboembolism is common post splenectomy. Our data showed that BMI ≥30 was asso-
ciated with a statistically significant increased risk of VTE, while the use of prophylactic anticoagulation was 
associated with reduced risk. Further prospective studies with larger samples are warranted and a splenectomy 
care plan may be helpful.   
1. Introduction 
Once considered a vestigial organ, the spleen has important hae-
matological and immunological functions. These include removing old 
and damaged red blood cells from the circulation, direct clearance of 
pathogens from the bloodstream and generation of immune responses to 
pathogens. 
Splenectomy remains a diagnostic and therapeutic option in a variety 
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of clinical circumstances. Therapeutic indications for splenectomy 
include benign haematological conditions such as refractory idiopathic 
thrombocytopenic purpura (ITP), warm autoimmune haemolytic 
anaemia (AIHA) and severe inherited haemolytic anaemias, such as 
hereditary spherocytosis. Splenectomy is also considered a treatment 
option for malignant conditions including lymphoma [1], chronic 
lymphoblastic leukaemia (CLL) and solid tumours with local invasion to 
the spleen. Other less common indications for removal include hyper-
splenism in thalassemia patients, traumatic or spontaneous splenic 
rupture, parenchymal splenic lesion, splenic abscess and splenic artery 
aneurysm. 
The spleen can be removed either via classical open laparotomy or 
laparoscopic surgical approaches. While postoperative morbidity and 
mortality outcomes are more favourable with laparoscopic approaches 
due to minimal surgical trauma and faster recovery [2,3], both ap-
proaches can be associated with serious complications. These include 
intra and postoperative haemorrhage, infections, malignancy, and 
thromboembolism. 
Infection risk is greatest in the early postoperative period, with an 
estimated 10% of splenectomies complicated by infection during the 
first 90 days [4]. The lifetime risk of overwhelming post-splenectomy 
infection is approximately 1–3% [5], with patients susceptible to 
infection by encapsulated organisms causing pneumococcal pneumonia 
(RR 2.1), meningitis (RR 2.4), and septicaemia (RR 3.4) [6]. 
Post-splenectomy infections may be fatal, particularly in younger, 
immunocompromised patients or those with malignant disease [6]. The 
increase risk of infections post splenectomy is attributed to the loss of the 
protective immunological function of the spleen. This risk of infection 
justifies the importance of vaccination and the use of prophylactic an-
tibiotics post splenectomy. 
Splenectomized patients have an increased risk of cancer, as well as 
increased cancer related mortality (RR 1.5 for both). A variety of cancer 
types have been reported with increased incidence post splenectomy, 
including solid neoplasms (lung, prostate, upper gastrointestinal and 
hepatic malignancies, RR 1.3–1.9); and haematologic malignancies 
(non-Hodgkin lymphoma, leukaemia & multiple myeloma, RR 1.8–6.0). 
Based on sparse data from animal studies, it has been suggested that 
splenectomy can induce of enhance tumour growth [7,8]. The risk for 
cancer development is greatest during the first two to five years 
post-splenectomy. However, a persistent risk beyond ten years 
post-splenectomy was demonstrated in one study [6]. 
Venous thromboembolism (VTE) is an infrequent but serious 
complication after splenectomy. Over the last two decades, there has 
been increased awareness about the risk of thromboembolism in the 
post-operative period, and post splenectomy in particular. There have 
been multiple studies to assess the incidence of venous thromboembo-
lism post splenectomy. In a large cohort study of more than 8000 pa-
tients, splenectomized patients had an increased risk of developing deep 
vein thrombosis (DVT) (RR = 2.18) and pulmonary embolism (RR =
2.24), but not coronary artery disease, or ischaemic stroke [6]. 
In another cohort study with a similar population, VTE occurred in 
1.9% of splenectomy patients within the first 90 days post splenectomy 
in contrast to 0.1% of general population controls [9]. 
In a third large cohort involving more than 1.5 million patients, the 
incidence of symptomatic venous thromboembolic events (VTE) was 
determined within a 3-month period after 76 different surgical pro-
cedures. Among 3833 patients post splenectomy, the incidence of VTE 
was 1.6%, compared with 0.8% in the general surgical population. The 
majority of VTE events (56%) were diagnosed post hospital discharge 
[10]. 
A higher incidence of post-splenectomy portal vein system throm-
bosis (PVST) in noncirrhotic patients was reported, at 6%–11% [2]. 
The increased risk of VTE appears to be due to a hypercoagulable 
state post splenectomy. Many mechanisms have been proposed 
including the transient thrombocytosis and leucocytosis secondary to 
absent splenic breakdown, platelet agglutination, increased rigidity of 
erythrocytes and disturbance and activation of vascular endothelium. In 
addition, changes in postoperative haemodynamics and the decrease in 
portal vein blood flow velocity were attributed to the development of 
postoperative PVST [6,11]. 
Multiple risk factors for post splenectomy VTE have been reported in 
the literature. Patient specific risk factors including advanced age [3] 
and active malignancy [9], procedure specific factors including lapa-
roscopic surgery [2,3] and thromboprophylaxis [2,11,12] and haema-
tological factors including platelet count ≥ 650 × 109/L [13] or < 50 ×
109/L [14] and D-dimer level of >500 lg/mL [13]. 
Additional risk factors have been identified among specific patient 
subgroups. For example, portal vein diameter >13 mm and enlarged 
splenic vein diameter were associated with increased risk of PVST after 
Laparoscopic Splenectomy in cirrhotic patients with hypersplenism due 
to portal hypertension [3]. Among thalassemia patients, spleen weight 
of more than 1.5 kg was the only independent factor associated with the 
presence of PVST [15]. 
2. Objectives 
The primary objective of the study was to evaluate the incidence of 
VTE post splenectomy and to identify the pre-operative, intra-operative 
and post-operative risk factors. 
The secondary objective was to assess local compliance with post- 
splenectomy prophylactic antibiotics and vaccination protocols. 
3. Methods & materials 
3.1. Patients 
The study was conducted in St James’s Hospital Dublin. All cases of 
splenectomy in St James’s Hospital between January 2007 and June 
2017 were identified by review of splenic specimens processed in St 
James’s Hospital histopathology laboratory during this time period. 
Splenic biopsy samples and external samples were excluded. Of the 98 
cases of splenectomy identified, incomplete data was available in 8 
patients and 5 patients were on therapeutic anticoagulation for VTE 
prior to the surgery; these were excluded from the analysis. The 
remaining 85 patients were included in the cohort. 
3.2. Clinical data 
We performed a retrospective observational analysis. Data was ob-
tained from both paper and electronic patient records. All patients who 
developed VTE were identified by confirmed venous thromboembolism 
radiologically post splenectomy. Details of the timing of VTE post 
splenectomy, vessels involved, and platelet count at the time of the event 
were collected. Multiple perioperative factors were studied. Preopera-
tive factors included patients’ age, gender, BMI, comorbid illness using 
Charlson Comorbidity Index, presence of malignancy, use of hormonal 
contraception, spleen size on imaging, preoperative platelet (PLT) 
count, preoperative use of anticoagulation or anti-platelets, indication 
and urgency of procedure. Intraoperative factors included type of sur-
gery, open or laparoscopic, complexity of the procedure, duration of 
anaesthesia, estimated blood loss and blood product transfusion. Post-
operative factors included length of hospital stay, wound complications 
and additional interventions, postoperative platelet count and use of 
anticoagulation or anti-platelets during admission and upon discharge. 
Histological data including splenic dimensions, weight and underlying 
histological diagnosis were also recorded. As a secondary aim, use of 
perioperative vaccination and postoperative prophylactic antibiotics 
was recorded. 
3.3. Statistical analyses 
Statistical analysis of the data was done using SPSS statistical 
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package. The influence of possible risk factors in the development of VTE 
was assessed by univariate and multivariate analyses. The demographic 
and clinical characteristics of the patients who developed VTE post- 
splenectomy and those who did not were compared and percentages, 
means (SDs), medians, IQRs given in each group where appropriate. 
Cross-tabulations and chi-squared and fishers exact tests (FET) were 
carried out to see was analyse any association between the factor and 
VTE incidence. The work has been reported in line with the STROCSS 
criteria [38]. 
4. Results 
A total of 85 patients who underwent splenectomy surgery were 
included in the study. The median age at time of the splenectomy was 48 
years with a male predominance (51.8 versus 48.2%) The indications for 
splenectomy were benign haematology (n = 29), malignant haematol-
ogy (n = 11), solid tumours (n = 9), traumatic rupture (n = 14), iatro-
genic trauma (n = 9), spontaneous rupture (n = 4) and others (n = 9). 
Details on the indications for splenectomy are demonstrated in Fig. 1 
and Table 1. 
Of the 85 patients included in the analysis, 6 patients developed VTE 
complications within 90 days post splenectomy (VTE incidence rate 
7.06%). 
Among the 6 VTE events, 5 (83.3%) were symptomatic. These con-
sisted of four splanchnic venous thromboses (2 in the splenic vein, 1 in 
the portal vein and 1 in the portal and splenic veins diagnosed by 
abdominal CT scan on days 6, 23, 16 and 9 respectively) and one non- 
fatal pulmonary embolism diagnosed by pulmonary CT angiogram on 
day 5. The asymptomatic event involved multiple upper and lower limb 
venous thromboses (including internal jugular, common femoral and 
common iliac veins) diagnosed incidentally by CT scan for restaging of 
malignancy on day 28 postoperatively. 
The median interval between splenectomy procedure and the VTE 
detection in our study was 16 days. The mean platelet count at the time 
of VTE events was 624 × 103 (range 204 × 109/L to 1414 × 109/L). All 
but one VTE event occurred after the patients were discharged from the 
hospital. Details of patients’ characteristics and VTE diagnosis are pre-
sented in Table 2. 
4.1. Pre-operative risks analysis 
Body Mass Index (BMI) was documented for 35 out of 85 patients. 
High BMI ≥30 was significantly associated with increased risk of VTE (p 
= 0.007). 60% (3/5) of patients in the VTE group had high BMI ≥ 30 in 
comparison to 20% (6/29) of patients in the non-VTE group. Female 
gender was not associated with increased VTE risk (p = 0.102). All 
patients who developed VTE underwent splenectomy in the elective 
setting. Age ≥50 (p = 0.58), active cancer (p = 1.000), high preopera-
tive platelets > 450 × 109/L (p = 0.364), pre-operative vaccinations (p 
= 0.233) and splenomegaly (defined by longitudinal diameter of spleen 
> 12 cm in imaging and/or splenic gross weight > 500 g) (p = 0.157) 
were associated with higher incidence of VTE with no statistical sig-
nificance. No significant differences were found in terms of the use of 
oral contraceptive pills (OCP) (p = 1.000), presence of documented 
chronic liver disease (p = 1.000), low preoperative platelet count < 100 
× 109/L (p = 0.576), indication for surgery (p = 0.851), emergency 
procedure (p = 0.086) and Charlson Comorbidity Score ≥ 3 (p = 1.000). 
Neither the use of preoperative antiplatelets medications (p = 0.576) or 
prophylactic anticoagulation (p = 1.000) altered the risk of post-
operative VTE (Table 3). 
4.2. Intraoperative risks analysis 
Intraoperative univariate analysis (Table 3) showed no difference in 
VTE risk between laparoscopic and open splenectomy (p = 0.69). VTE 
events complicated both procedures equally. The complexity of the 
surgery (p = 1.000) and the intraoperative red cell transfusion (p =
0.395) as well as transfusion of other blood components were not 
associated with increased risk of VTE with no significant inter-group 
difference was observed. The mean duration of surgery (p = 0.547) as 
well as the mean blood loss (p = 0.205) were similar in the VTE and non- 
VTE groups. 
4.3. Postoperative risks analysis 
The use of prophylactic anticoagulation post discharge was the only 
postoperative risk factor associated with significantly lower VTE risk 
(Table 3). 2 patients developed VTE events during hospital admission 
and were discharged on therapeutic anticoagulation, so were excluded 
from the analysis. None of the remaining 4 patients in the VTE group (0/ Fig. 1. Indications for splenectomy.  
Table 1 
Detailed indications for splenectomy.  
Indications for Splenectomy  
Indication No. of Patients 
Benign haematology:  
ITP 21 
AIHA 4 
Hereditary spherocytosis 4 
Total 29 




Solid tumours  
Gastric cancer 3 
Invasive colonic cancer 1 
Metastatic ovarian cancer 1 
Metastatic cervical cancer 1 
Melanoma 1 
Metastatic adenocarcinoma unknown primary 2 
Total 9 
Traumatic splenic rupture 14 
Iatrogenic splenic trauma 9 
Spontaneous splenic rupture 4 
Others:  
Ruptured splenic artery aneurysm 2 
AAA repair 2 
Splenic AV fistula repair 1 
Calcified splenic cyst 1 
Splenic abscess 1 
Pancreaticodudenal fistula 1 
Distal Pancreatic lesion 1 
Total 9  
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4) had received prophylactic anticoagulation upon discharge, in com-
parison to 8/79 in the non-VTE group (p = 0.005). Mean duration of 
hospitalization was similar in VTE and non-VTE groups, 9.5 and 11 days 
respectively with no statistical significance (p = 0.419). No other post-
operative variables significantly predicted VTE risk, including; malig-
nant pathology of the spleen (p = 1.000), use of prophylactic 
anticoagulation during hospital stay (p = 1.000), wound infection (p =
1.000), intra-abdominal collection drainage or re-operation (p = 0.285), 
discharge on antiplatelets (p = 1.000) and highest recorded post-
operative platelet count of >450 × 109/L and >1000 × 109/L within 
four weeks post-surgery (p = 0.660 and 1.000 respectively). 
When multiple logistic regression analysis was conducted in a step-
wise method, high BMI ≥30 and the use of prophylactic anticoagulation 
after discharge are the only significant independent risk factors for VTE. 
Demographic and perioperative clinical characteristics in the VTE 
and non-VTE groups are shown in Table 3. 
Perioperative vaccinations and prophylactic antibiotics: 
Most patients (89.4%) included in the analysis received periopera-
tive vaccinations. 32 patients (37.6%) received preoperative vaccina-
tions and 44 patients (51.8%) received postoperative vaccinations. 
However, vaccinations were not documented for 9/85 patients (10.6%). 
All except 2 patients (98%) were prescribed prophylactic antibiotics 
upon discharge. 
5. Discussion 
Splenectomy remains a therapeutic option for a variety of clinical 
conditions; benign and malignant. One third of patients in our cohort 
(34%) underwent splenectomy due to an underlying benign haemato-
logical condition. However, recently due to the introduction of alter-
native novel medical treatment options, fewer patients will be 
considered for surgical splenectomy. 
In this study, the incidence of VTE post splenectomy was 7.05%. The 
majority of the VTE events were intraabdominal with a PVST incidence 
rate of 4.7%. These incidence rates are higher than the 0.63% VTE risk 
seen in previous large study of more than 180,000 patients who un-
derwent vascular and general surgical procedures [16]. 
The reported incidence of PVST after splenectomy is variable. Lower 
incidence rates of 1.6% and 2% reported in two retrospective American 
and Dutch studies respectively [17,18]. Higher incidence rates have 
been reported in patients with B-thalassemia (8.3%), hereditary hae-
molytic anaemias (12.3%) [15], haematological malignancies (7.2%) 
[19], noncirrhotic patients (6–11%) [3] and cirrhotic patients with 
hypersplenism (24–40%) [3,14]. 
In addition, cases of VTE are often asymptomatic and are only 
detected on pre-emptive screening. 8–37% of all splenectomized pa-
tients found to have PVST in three studies in which patients were 
screened for PVST by doppler ultrasound [20,21] or contrast enhanced 
computed tomography (CT) scans [22], of which only 2–15% were 
symptomatic [9]. The variable incidence rates can be related to different 
sample sizes, the diagnostic modalities used and whether the patients 
were diagnosed upon screening or when symptomatic. Despite this 
variation, most of these studies suggested that splenectomy is associated 
with a significant risk of venous thromboembolism and pre-emptive 
monitoring for PVST by regular patient examination or screening im-
aging may ensure timely diagnosis and treatment to avoid further 
life-threatening complications [3,14,23]. 
In our study, all VTE events were detected between 5 and 28 days 
post splenectomy which probably indicates a higher thrombosis risk 
within the first 4 weeks post-surgery and the need for heightened vigi-
lance and consideration of this severe complication. However, a 
persistent thrombosis risk more than ten years following the procedure 
was shown in one study suggesting a life-long susceptibility state [6]. 
Analysis of preoperative risk factors showed that BMI ≥30 was an 
independent risk factor for VTE development. Obesity is known as a risk 
factor for venous thrombosis [24]. It has been suggested that obesity is 
associated with inflammation and reduction in fibrinolysis with conse-
quent increased thrombotic risk. There is a high incidence of obesity in 
the Irish population (60%) as revealed by HSE stats in April 2018. 
Predictions from UK Foresight Model indicate that 90% of Irish popu-
lation will be overweight or obese by 2030. 
The presence of active cancer has been shown to be associated with 
increased VTE risk after various general and vascular surgeries [10,16], 
as well as post splenectomy [9]. However, this association was not found 
in our study. Indeed, 50% of cases of VTE in our cohort occurred in 
patients with underlying ‘low risk’ indications, such as autoimmune 
disease and traumatic splenectomy. It was initially proposed that the 
rationale behind that was that some patients with underlying malig-
nancy were discharged home on extended prophylaxis which altered 
their risk of VTE development. However, multivariate analysis excluded 
prophylaxis as a confounding factor. 
In a study done by Rogers et al. emergency surgery was found to be 
associated with increased risk of VTE after general and vascular pro-
cedures [16]. However, this correlation was not demonstrated in our 
study as all VTE events occurred after elective procedures. Although 
found to be independent predictors for VTE in multiple previous studies, 
advanced age [3,10,25], female gender [16,24] and splenomegaly [9, 
15] were not associated with increased VTE risk in our cohort. 
Worthy to mention that degree of portal hypertension manifested by 
wider splenic vein [26] and portal vein diameters [2] were attributed to 
higher risk of PVST post splenectomy in previous studies, these pa-
rameters were not assessed in our study. In addition, history of prior VTE 
was reported to have a strong association with VTE post cancer surgeries 
[25,27] and other different surgical procedures [10], however, this was 
not evaluated in our study as none of the VTE patients had prior VTE 
event. 
In two previous studies, a higher rate of PVST was demonstrated post 
laparoscopic splenectomy with or without azygoportal disconnection in 
patients with liver cirrhosis and hypersplenism. It was suggested that the 
higher incidence of PVST in patients who have undergone laparoscopic 
Table 2 
Details of patients with VTE.  










VTE location PLT count on 
diagnosis 
70 F 30.8 Yes Iatrogenic rupture Elective Laparoscopic 28 No RIJ, RCF, RCI 
veins 
444 
62 F 25.57 No AV fistula of splenic 
artery 
Elective Open 6 Yes Splenic vein 842 
42 F 48 No Refractory ITP Elective Open 5 Yes Pulmonary 
artery 
204 
67 M 23.38 Yes B-Cell lymphoma Elective Open 23 Yes PSVT 214 
38 F 34.91 No Refractory ITP Elective Laparoscopic 9 Yes PSVT 628 
19 F N/A No Hereditary 
spherocytosis 
Elective Laparoscopic 16 Yes PSVT 1414 
BMI, body mass index; POD, postoperative day; VTE, venous thromboembolism; PLT, platelets; ITP, immune thrombocytopenic purpura; RIJ, right internal jugular; 
RCF, right common femoral; RCI, right common iliac; PSVT Portal-splenic venous thrombosis, N/A, not available. 
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procedure may be associated with CO2 pneumoperitoneum causing a 
hypercoagulable state and the technique and the instruments used to 
disconnect the splenic hilar vessels [2,3]. Yet, no difference in the 
incidence of PVST between open surgery and laparoscopic surgery was 
shown in one study [28]. Likewise, in our study both procedures were 
associated with similar VTE risk. While duration of anaesthesia of ≥3.5 h 
and >2 h strongly predicted the occurrence of postoperative VTE after 
orthopaedic and cancer surgeries respectively [2,25], this was not 
confirmed in our study. Although several studies described blood 
transfusions as a risk factor for postoperative VTE [3,16,29–31]; how-
ever, neither intraoperative blood transfusion nor intraoperative blood 
loss were associated with an increased VTE risk in this cohort. 
In our study extended prophylactic anticoagulation on discharge was 
a significant negative predictor of VTE (p = 0.005). The effectiveness 
and safety of prophylactic anticoagulation use for postoperative VTE 
prevention has been explored and confirmed in several different set-
tings, including surgery for malignant disease [27,32,33], orthopaedic 
surgery [34,35], and splenectomy in cirrhotic patients. In a study by Lai 
et al. involving more than 300 patients, early use of LMWH for 5 days 
post-surgery followed by a long-term maintenance therapy with 
warfarin and aspirin for one month was safe and effective method for 
PVST prevention after splenectomy with gastroesophageal devasculari-
zation [11]. In another retrospective cohort study of 75 consecutive 
cirrhotic patients who underwent laparoscopic splenectomy and azy-
goportal disconnection, the incidence of PVST was significantly lower in 
patient received postoperative thromboprophylaxis with warfarin than 
aspirin [2]. Another study reported that low molecular weight heparin 
(LMWH) was also effective in reducing the incidence of PVST in the 
same group [12]. High platelet count was associated with the develop-
ment of PVST in previous studies [9,13,15], for which long-term anti-
platelet therapy for high-risk patients has been recommended [15,36, 
37]. Yet, this was not confirmed for the patient population described 
here. Wound infection has been reported among fifteen variables inde-
pendently associated with increased risk of VTE after general and 
vascular surgery [2]; however, this correlation was not shown in our 
cohort. Early ambulation was described as a significant protective factor 
of VTE post total hip arthroplasty [24], while prolonged bed rest was 
associated with a higher VTE risk post cancer surgery [25], those were 
difficult to be assessed in our study retrospectively. 
The limitations of our study were its retrospective design and sample 
size We lacked complete data, including patient’s body mass index, and 
details on postoperative immobility. Despite these limitations, a large 
number of perioperative risk factors have been assessed in the current 
study. 
In conclusion, our study showed a high incidence of venous throm-
boembolism in patients post splenectomy, the majority of VTE involved 
the portal venous system. Patients require close follow-up for the 
development of PVST. Algorithms for investigation of abdominal pain 
and fever post splenectomy should consider PVST high in the differen-
tial. High BMI ≥30 was a significant positive predictor of VTE, while the 
use of extended prophylactic anti-coagulation was a significant negative 
predictor. To further reduce the incidence of symptomatic thrombo-
embolism, efforts to improve recording of BMI on all patients and ac-
curate in-hospital and post discharge thromboprophylaxis especially in 
overweight patients would be beneficial. Further prospective studies 
and large randomized controlled trials to confirm these findings are 
warranted. A splenectomy care plan to consider individual risks may be 
helpful. Compliance with peri-operative vaccinations and prophylactic 
antibiotic use was good but ongoing education of staff and patients to 
maintain and improve practice is recommended. 
Ethical approval 
This study was performed as a retrospective audit and was given 
local authority to proceed through our hospital research and innovation 
office. Formal Ethical approval was not sought given the retrospective 
Table 3 
Demographic and perioperative clinical characteristics in the VTE and non-VTE 
groups.  







Age ≥ 50 3/6 (50%) 36/79 
(45.6%) 
1.000 





BMI ≥ 30a 3/5 (60%) 6/29 (20%) 0.007 
OCPb 0/5 (0%) 3/36 (8%) 1.000 





CLD 0/6 (0%) 2/79 (2.5%) 1.000 





Pre- operative PLT > 450 × 103 1/6 
(16.7%) 
5/79 (6.3%) 0.364 










Pre- operative vaccination 4/6 
(66.7%) 
28/70 (40%) 0.233 
Emergency surgery 0/6 (0%) 30/79 (38%) 0.086 
Splenomegalyc 3/6 (50%) 18/79 
(22.8%) 
0.157 






Laparoscopic surgery 3/6 (50%) 33/79 
(41.8%) 
0.695 










Platelets transfusion 0/6 (0%) 15/79 
(19.0%) 
0.585 
Plasma transfusion 0/6 (0%) 14/79 
(17.7%) 
0.583 
Fibrinogen transfusion 0/6 (0%) 3/79 (3.8%) 1.000 
Mean duration of surgery (hr) 2.87 2.87 0.547 
Mean intra-operative blood loss (ml) 300 575 0.205 
Postoperative variable 
Mean duration of hospital stay (day) 9.5 11 0.419 
























Discharge on anticoagulation 0/4 (0%) 8/79 (10.1%) 0.005 















BMI, body mass index; OCP, oral contraceptive pills; CLD, chronic liver disease; 
PLT, platelets. 
a BMI was only documented for total of 34 patients (n = 34). 
b OCP analysis was done among females (n = 41). 
c Splenomegaly defined by longitudinal diameter of the spleen >12 cm in 
imaging and/or splenic gross weight of >500 g. 
d Two patients developed VTE during admission and were discharged on 
therapeutic anticoagulation, so excluded from the analysis. 
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